Diabetics use glucose monitors. Should non-diabetics use them too?
Not everyone in the health field is so bullish on the prospects of CGMs for everyone, and question whether digging in too ...
Abbott Q3: Strong Growth In Medical Device And Pharma
Abbott's recent results show 7.6% organic revenue growth, driven by medical devices and pharmaceuticals. Click here to read ...
health.economictimes.indiatimes22h
Abbott bumps up profit forecast on strong medical device sales
Increasing diabetes care awareness, wider insurance coverage and preference for devices that do not need finger pricks have ...
Mercy Places First Commercial Eversense 365: The World's First and Only 365-Day Continuous Glucose Monitor
Senseonics Holdings, Inc. (NYSE American: SENS) ("Senseonics" or the "Company"), a medical technology company focused on the ...
Senseonics to Host Virtual KOL Event on Eversense 365: FDA Clearance and Commercialization Plans for the World's First One-Year CGM System
Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for ...
Glucose monitors for diabetes have finally been funded – but there's a problem
There are problems within the health system that mean full patient access to training on how to use the insulin pumps will ...
Abbott1d
Strong Performance by Abbott’s Base Business Drives Q3 Earnings
Abbott’s earnings for the third quarter (Q3) of 2024 saw global sales reach $10.6 billion, a strong performance driven by the ...
Hosted on MSN54m
Abbott reports sales of $10.6bn for Q3 2024
Abbott Laboratories has reported sales of $10.6bn for the third quarter (Q3) of 2024, as against $10.4bn in Q2 2024, with ...
Millions of UK diabetes patients urged to report insulin device issues amid health risks
The Medicines and Healthcare products Regulatory Agency is urging people to report any safety concerns they have about ...